Calcium channel blocker use and risk of Parkinson's disease

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1818-1822

  Simon, Kelly Claire ^a   Gao, Xiang ^a,b   Chen, Honglei ^c   Schwarzschild, Michael A ^d   Ascherio, Alberto ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antihypertensive; Calcium channel blockers; Parkinson's disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; MALE; NURSES; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 77956860900     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23191     Document Type: Article

References (11)

1. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y. Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 1997;50:79-88.
2. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007;6:933-938. (Pubitemid 47405004)
3. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086.
4. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008;70(16 Pt 2):1438-1444.
5. Ton TG, Heckbert SR, Longstreth WT, Jr, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord 2007;13:165-169.
6. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
7. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, Tuttle JB. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 1997;68:1221-1233.
8. Wilson JA, Lau YS, Gleeson JG, Wilson JS. The action of MPTP on synaptic transmission is affected by changes in Ca2+ concentrations. Brain Res 1991;541:342-346.
9. Forte G, Bocca B, Senofonte O, et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004;111:1031-1040.
10. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007;6:337-350.
11. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009;72:578-579.